Horng-Jyh Harn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Horng-Jyh Harn has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Chang-Chieh Wu
Department of Surgery, Tri-Service General Hospital, 325 Chengung Rd, Sec 2, Taipei, 114 Taiwan
1 shared publication Chau‐Chin Lee
Department of Radiology
1 shared publicationNu‐Man Tsai
Department of Applied Life Science, Asia University, Taichung, Taiwan
1 shared publicationPo‐Chen Lin
Institute of Medical Sciences
1 shared publication- Shee-Ping Chen
Tzu-Chi Stem Cell Centre, Buddhist Tzu-Chi General Hospital, Hualien, Taiwan
1 shared publication - Shih-Tzu Tsai
Department of Family Medicine, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
1 shared publication
Latest Publications
- Open Access
- 21 August 2006
- Published by Wiley in Journal of Neurochemistry
- Vol. 99 (4) , 1251-1262
The natural compound n‐butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo3
The naturally‐occurring compound, n‐butylidenephthalide (BP), which is isolated from the chloroform extract of Angelica sinensis (AS‐C), has been investigated with respect to the treatment of angina. In this study, we have examined the anti‐tumor effects of n‐butylidenephthalide on glioblastoma multiforme (GBM) brain tumors both in vitro and in vivo. In vitro, GBM cells were treated with BP, and the effects of proliferation, cell cycle and apoptosis were determined. In vivo, DBTRG‐05MG, the human GBM tumor, and RG2, the rat GBM tumor, were injected subcutaneously or intracerebrally with BP. The effects on tumor growth were determined by tumor volumes, magnetic resonance imaging and survival rate. Here, we report on the potency of BP in suppressing growth of malignant brain tumor cells without simultaneous fibroblast cytotocixity. BP up‐regulated the expression of Cyclin Kinase Inhibitor (CKI), including p21 and p27, to decrease phosphorylation of Rb proteins, and down‐regulated the cell‐cycle regulators, resulting in cell arrest at the G0/G1 phase for DBTRG‐05MG and RG2 cells, respectively. The apoptosis‐associated proteins were dramatically increased and activated by BP in DBTRG‐05MG cells and RG2 cells, but RG2 cells did not express p53 protein. In vitro results showed that BP triggered both p53‐dependent and independent pathways for apoptosis. In vivo, BP not only suppressed growth of subcutaneous rat and human brain tumors but also, reduced the volume of GBM tumors in situ, significantly prolonging survival rate. These in vitro and in vivo anti‐cancer effects indicate that BP could serve as a new anti‐brain tumor drug.
- 21 August 2006
- Published by Wiley in Journal of Neurochemistry
- Vol. 99 (4) , 1251-1262
Open AccessThe natural compound n‐butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo3
The naturally‐occurring compound, n‐butylidenephthalide (BP), which is isolated from the chloroform extract of Angelica sinensis (AS‐C), has been investigated with respect to the treatment of angina. In this study, we have examined the anti‐tumor effects of n‐butylidenephthalide on glioblastoma multiforme (GBM) brain tumors both in vitro and in vivo. In vitro, GBM cells were treated with BP, and the effects of proliferation, cell cycle and apoptosis were determined. In vivo, DBTRG‐05MG, the human GBM tumor, and RG2, the rat GBM tumor, were injected subcutaneously or intracerebrally with BP. The effects on tumor growth were determined by tumor volumes, magnetic resonance imaging and survival rate. Here, we report on the potency of BP in suppressing growth of malignant brain tumor cells without simultaneous fibroblast cytotocixity. BP up‐regulated the expression of Cyclin Kinase Inhibitor (CKI), including p21 and p27, to decrease phosphorylation of Rb proteins, and down‐regulated the cell‐cycle regulators, resulting in cell arrest at the G0/G1 phase for DBTRG‐05MG and RG2 cells, respectively. The apoptosis‐associated proteins were dramatically increased and activated by BP in DBTRG‐05MG cells and RG2 cells, but RG2 cells did not express p53 protein. In vitro results showed that BP triggered both p53‐dependent and independent pathways for apoptosis. In vivo, BP not only suppressed growth of subcutaneous rat and human brain tumors but also, reduced the volume of GBM tumors in situ, significantly prolonging survival rate. These in vitro and in vivo anti‐cancer effects indicate that BP could serve as a new anti‐brain tumor drug.
- Open Access
- 29 March 2006
- Published by Springer Nature in BMC Cancer
- Vol. 6 (1) , 83
Single nucleotide polymorphisms of the APC gene and colorectal cancer risk: a case-control study in Taiwan
Background: Colorectal cancer (CRC), which has become especially prevalent in developed countries, is currently the third highest cause of cancer mortality in Taiwan. Mutation of the adenomatous polyposis coli (APC) gene, a tumour suppressor, is thought to be an early event in colorectal tumourigenesis. To date, however, no large-scale screening for APC gene variants in Chinese subjects has been performed. The present study was undertaken to identify APC gene variants that are significantly associated with the occurrence of CRC in Taiwanese subjects. Methods: In order to compare the genotype distribution of variant sites, the full-length APC genes of 74 healthy individuals and 80 CRC patients were sequenced. Results: Among the 154 Taiwanese subjects examined in this study, three new mutations, but no previously reported mutations, were found. One deletion at codon 460 leading to a frameshift and two missense mutations resulting in p.V1125A and p.S1126R substitutions were identified. Additionally, three high risk genotypes associated with three single nucleotide polymorphisms and one low risk genotype at codon 1822 were identified. Conclusion: The findings of this case-control study are consistent with the proposal that Taiwanese subjects differ from other subjects with respect to phenotypic presentation of APC and CRC risk.
- 29 March 2006
- Published by Springer Nature in BMC Cancer
- Vol. 6 (1) , 83
Open AccessSingle nucleotide polymorphisms of the APC gene and colorectal cancer risk: a case-control study in Taiwan
Background: Colorectal cancer (CRC), which has become especially prevalent in developed countries, is currently the third highest cause of cancer mortality in Taiwan. Mutation of the adenomatous polyposis coli (APC) gene, a tumour suppressor, is thought to be an early event in colorectal tumourigenesis. To date, however, no large-scale screening for APC gene variants in Chinese subjects has been performed. The present study was undertaken to identify APC gene variants that are significantly associated with the occurrence of CRC in Taiwanese subjects. Methods: In order to compare the genotype distribution of variant sites, the full-length APC genes of 74 healthy individuals and 80 CRC patients were sequenced. Results: Among the 154 Taiwanese subjects examined in this study, three new mutations, but no previously reported mutations, were found. One deletion at codon 460 leading to a frameshift and two missense mutations resulting in p.V1125A and p.S1126R substitutions were identified. Additionally, three high risk genotypes associated with three single nucleotide polymorphisms and one low risk genotype at codon 1822 were identified. Conclusion: The findings of this case-control study are consistent with the proposal that Taiwanese subjects differ from other subjects with respect to phenotypic presentation of APC and CRC risk.